• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CUV 0.45% $15.69

CLINUVEL PHARMACEUTICALS LIMITED - Announcements

Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical... Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).More

Announcements


CUV Presentation to international porphyria patient group08/02/16 download Created with Sketch. 1.74MB
CUV Appendix 4C - quarterlyPRICE SENSITIVE28/01/16 download Created with Sketch. 172.15KB
CUV Change in substantial holding25/01/16 download Created with Sketch. 1.25MB
CUV CEO Brief20/01/16 download Created with Sketch. 270.13KB
CUV Change in substantial holding18/01/16 download Created with Sketch. 246.56KB
CUV Update on North American vitiligo program for SCENESSEPRICE SENSITIVE03/12/15 download Created with Sketch. 132.79KB
CUV Positive preliminary results in Singaporean vitiligo studyPRICE SENSITIVE03/12/15 download Created with Sketch. 133.07KB
CUV Results of Meeting24/11/15 download Created with Sketch. 102KB
CUV CEO's AGM Presentation24/11/15 download Created with Sketch. 2.98MB
CUV Chairman's Address to Shareholders24/11/15 download Created with Sketch. 102.79KB
CUV Change in substantial holding04/11/15 download Created with Sketch. 3.33MB
CUV Appendix 4C - quarterlyPRICE SENSITIVE30/10/15 download Created with Sketch. 137.79KB
CUV Appendix 4G and Corporate Governance Statement23/10/15 download Created with Sketch. 679.3KB
CUV Annual Report to shareholders23/10/15 download Created with Sketch. 3.46MB
CUV Notice of Annual General Meeting/Proxy Form23/10/15 download Created with Sketch. 651.05KB
CUV Change in substantial holding07/10/15 download Created with Sketch. 559.76KB
CUV AGM Date06/10/15 download Created with Sketch. 254.13KB
CUV FDA Meeting05/10/15 download Created with Sketch. 268.27KB
CUV Becoming a substantial holder23/09/15 download Created with Sketch. 773.09KB
CUV SCENESSE released for European DistributionPRICE SENSITIVE21/09/15 download Created with Sketch. 284.3KB
CUV Preliminary Final ReportPRICE SENSITIVE31/08/15 download Created with Sketch. 1.03MB
CUV FDA grants Clinuvel a Type C MeetingPRICE SENSITIVE27/08/15 download Created with Sketch. 143.62KB
CUV Appendix 4C - quarterlyPRICE SENSITIVE31/07/15 download Created with Sketch. 138.06KB
CUV Ceasing to be a substantial holder30/07/15 download Created with Sketch. 159.82KB
CUV Clinuvel Newsletter - July 201515/07/15 download Created with Sketch. 175.38KB
CUV NEJM publishes Phase III SCENESSE studiesPRICE SENSITIVE02/07/15 download Created with Sketch. 134.46KB
CUV SCENESSE Commercialisation UpdatePRICE SENSITIVE05/06/15 download Created with Sketch. 282.58KB
CUV Clinuvel announces innovative melanocortinPRICE SENSITIVE05/05/15 download Created with Sketch. 131.32KB
CUV Appendix 4C - quarterlyPRICE SENSITIVE27/04/15 download Created with Sketch. 137.52KB
CUV Clinuvel Relocates Melbourne Office31/03/15 download Created with Sketch. 205.87KB
CUV Appendix 3B20/03/15 download Created with Sketch. 547.71KB
CUV SCENESSE data presented at US dermatology conference20/03/15 download Created with Sketch. 119.32KB
CUV SCENESSE breakthrough featured in peer-reviewed editorial20/03/15 download Created with Sketch. 115.97KB
CUV Clinuvel Newsletter - March 201512/03/15 download Created with Sketch. 1.09MB
MPL +S&P DJ Indices Announces March Quarterly ReviewPRICE SENSITIVE06/03/15 download Created with Sketch. 100.19KB
CUV Appendix 3B02/03/15 download Created with Sketch. 550KB
CUV Half Yearly Report and AccountsPRICE SENSITIVE25/02/15 download Created with Sketch. 265.55KB
CUV Appendix 4C - quarterlyPRICE SENSITIVE30/01/15 download Created with Sketch. 138.2KB
CUV Change of Director's Interest Notice23/01/15 download Created with Sketch. 728.77KB
CUV Appendix 3B23/01/15 download Created with Sketch. 549.52KB
CUV Initial Director's Interest Notice21/01/15 download Created with Sketch. 342.33KB
CUV Clinuvel appoints new Non-Executive Director21/01/15 download Created with Sketch. 210.85KB
CUV European Commission approves SCENESSEPRICE SENSITIVE23/12/14 download Created with Sketch. 275.65KB
CUV Change of Director's Interest Notice x 323/12/14 download Created with Sketch. 681.88KB
CUV Appendix 3B23/12/14 download Created with Sketch. 544.6KB
CUV Long term use of SCENESSE in EPP published in BJD15/12/14 download Created with Sketch. 121.02KB
CUV Change in substantial holding05/12/14 download Created with Sketch. 278.54KB
CUV Change of Director's Interest Notice * 404/12/14 download Created with Sketch. 857.15KB
CUV Appendix 3B04/12/14 download Created with Sketch. 548.6KB
CUV Investor Update Presentation04/12/14 download Created with Sketch. 1.13MB
CUV Results of Meeting28/11/14 download Created with Sketch. 101.25KB
CUV Chairman's Address28/11/14 download Created with Sketch. 87.82KB
CUV CEO's AGM presentation28/11/14 download Created with Sketch. 4.08MB
CUV Letter to Shareholders05/11/14 download Created with Sketch. 256.29KB
CUV Letter to Shareholders03/11/14 download Created with Sketch. 299.92KB
CUV Appendix 4C - quarterlyPRICE SENSITIVE29/10/14 download Created with Sketch. 150.11KB
CUV Clinuvel to host investor teleconference28/10/14 download Created with Sketch. 83.46KB
CUV Annual Report to shareholders27/10/14 download Created with Sketch. 1.18MB
CUV Notice of Annual General Meeting/Proxy Form27/10/14 download Created with Sketch. 665.02KB
CUV SCENESSE attains breakthrough European Market AuthorisationPRICE SENSITIVE27/10/14 download Created with Sketch. 131.83KB
CUV Trading HaltPRICE SENSITIVE24/10/14 download Created with Sketch. 240.88KB
CUV AGM Date10/10/14 download Created with Sketch. 216.29KB
CUV Lapse and Forfeit of Unlisted Conditional Performance Rights10/10/14 download Created with Sketch. 187.82KB
CUV SCENESSE data to be presented at EADV conference08/10/14 download Created with Sketch. 92.14KB
CUV EMA Oral Explanation UpdatePRICE SENSITIVE26/09/14 download Created with Sketch. 90.07KB
CUV Clinuvel invited to present at EMA's CHMP plenary session22/09/14 download Created with Sketch. 299.84KB
CUV Clinuvel enters a joint venture with Biotech Lab SingaporePRICE SENSITIVE19/09/14 download Created with Sketch. 281.14KB
CUV JAMA Dermatology publishes SCENESSE vitiligo study resultsPRICE SENSITIVE19/09/14 download Created with Sketch. 152KB
CUV Response to ASX Price QueryPRICE SENSITIVE16/09/14 download Created with Sketch. 536.23KB
CUV Change in substantial holding12/09/14 download Created with Sketch. 890.53KB
CUV Change in substantial holding11/09/14 download Created with Sketch. 1.12MB
CUV Preliminary Final ReportPRICE SENSITIVE25/08/14 download Created with Sketch. 2.05MB
CUV Chairman's Update18/08/14 download Created with Sketch. 292.16KB
CUV Clinuvel declines unsolicited proposal from RetrophinPRICE SENSITIVE08/08/14 download Created with Sketch. 118.72KB
CUV Appendix 3B07/08/14 download Created with Sketch. 549.84KB
CUV Appendix 4C - quarterlyPRICE SENSITIVE31/07/14 download Created with Sketch. 33.46KB
CUV Final Director's Interest Notice31/07/14 download Created with Sketch. 109.47KB
CUV Becoming a substantial holder30/07/14 download Created with Sketch. 265.21KB
CUV Becoming a substantial holder30/07/14 download Created with Sketch. 257.08KB
CUV Proposal to acquire all the outstanding shares in Clinuvel P28/07/14 download Created with Sketch. 999.46KB
CUV Mr Jack Wood28/07/14 download Created with Sketch. 85.15KB
CUV Clinuvel receives an unsolicited bid for the CompanyPRICE SENSITIVE28/07/14 download Created with Sketch. 89.73KB
CUV Clinuvel Newsletter July 201416/07/14 download Created with Sketch. 328.13KB
CUVUS orphan-drug designation in Hailey-Hailey DiseasePRICE SENSITIVE22/05/14 download Created with Sketch. 313.99KB
CUVs.708A Notice20/05/14 download Created with Sketch. 34.01KB
CUVBecoming a substantial holder20/05/14 download Created with Sketch. 52.63KB
CUVAppendix 3B20/05/14 download Created with Sketch. 512.46KB
CUVEuro orphan designation in Hailey-Hailey Disease - SCENESSE19/05/14 download Created with Sketch. 118.76KB
CUVManagement UpdatePRICE SENSITIVE19/05/14 download Created with Sketch. 415.41KB
CUVClinuvel placementPRICE SENSITIVE14/05/14 download Created with Sketch. 427.27KB
CUVTrading Halt Request12/05/14 download Created with Sketch. 155.48KB
CUVTrading HaltPRICE SENSITIVE12/05/14 download Created with Sketch. 77.85KB
CUVPhase II vitiligo study commences in SingaporePRICE SENSITIVE06/05/14 download Created with Sketch. 368.83KB
CUVAppendix 4C - quarterlyPRICE SENSITIVE17/04/14 download Created with Sketch. 150.32KB
CUVLapse and Forfeit of Unlisted Conditional Performance Rights14/04/14 download Created with Sketch. 189.38KB
CUVClinuvel Newsletter April 201414/04/14 download Created with Sketch. 1.72MB
CUVSCENESSE data to feature at American Academy of Dermatology20/03/14 download Created with Sketch. 129.81KB
CUVHalf Yearly Report and AccountsPRICE SENSITIVE26/02/14 download Created with Sketch. 320.92KB
CUVPhase II study starts in skin disorder Hailey-Hailey DiseasePRICE SENSITIVE10/02/14 download Created with Sketch. 301.25KB
CUVClinuvel Newsletter04/02/14 download Created with Sketch. 391.27KB
CUV Presentation to international porphyria patient group
08/02/16 download Created with Sketch. 1.74MB
CUV Appendix 4C - quarterly
28/01/16PRICE SENSITIVE download Created with Sketch. 172.15KB
CUV Change in substantial holding
25/01/16 download Created with Sketch. 1.25MB
CUV CEO Brief
20/01/16 download Created with Sketch. 270.13KB
CUV Change in substantial holding
18/01/16 download Created with Sketch. 246.56KB
CUV Update on North American vitiligo program for SCENESSE
03/12/15PRICE SENSITIVE download Created with Sketch. 132.79KB
CUV Positive preliminary results in Singaporean vitiligo study
03/12/15PRICE SENSITIVE download Created with Sketch. 133.07KB
CUV Results of Meeting
24/11/15 download Created with Sketch. 102KB
CUV CEO's AGM Presentation
24/11/15 download Created with Sketch. 2.98MB
CUV Chairman's Address to Shareholders
24/11/15 download Created with Sketch. 102.79KB
CUV Change in substantial holding
04/11/15 download Created with Sketch. 3.33MB
CUV Appendix 4C - quarterly
30/10/15PRICE SENSITIVE download Created with Sketch. 137.79KB
CUV Appendix 4G and Corporate Governance Statement
23/10/15 download Created with Sketch. 679.3KB
CUV Annual Report to shareholders
23/10/15 download Created with Sketch. 3.46MB
CUV Notice of Annual General Meeting/Proxy Form
23/10/15 download Created with Sketch. 651.05KB
CUV Change in substantial holding
07/10/15 download Created with Sketch. 559.76KB
CUV AGM Date
06/10/15 download Created with Sketch. 254.13KB
CUV FDA Meeting
05/10/15 download Created with Sketch. 268.27KB
CUV Becoming a substantial holder
23/09/15 download Created with Sketch. 773.09KB
CUV SCENESSE released for European Distribution
21/09/15PRICE SENSITIVE download Created with Sketch. 284.3KB
CUV Preliminary Final Report
31/08/15PRICE SENSITIVE download Created with Sketch. 1.03MB
CUV FDA grants Clinuvel a Type C Meeting
27/08/15PRICE SENSITIVE download Created with Sketch. 143.62KB
CUV Appendix 4C - quarterly
31/07/15PRICE SENSITIVE download Created with Sketch. 138.06KB
CUV Ceasing to be a substantial holder
30/07/15 download Created with Sketch. 159.82KB
CUV Clinuvel Newsletter - July 2015
15/07/15 download Created with Sketch. 175.38KB
CUV NEJM publishes Phase III SCENESSE studies
02/07/15PRICE SENSITIVE download Created with Sketch. 134.46KB
CUV SCENESSE Commercialisation Update
05/06/15PRICE SENSITIVE download Created with Sketch. 282.58KB
CUV Clinuvel announces innovative melanocortin
05/05/15PRICE SENSITIVE download Created with Sketch. 131.32KB
CUV Appendix 4C - quarterly
27/04/15PRICE SENSITIVE download Created with Sketch. 137.52KB
CUV Clinuvel Relocates Melbourne Office
31/03/15 download Created with Sketch. 205.87KB
CUV Appendix 3B
20/03/15 download Created with Sketch. 547.71KB
CUV SCENESSE data presented at US dermatology conference
20/03/15 download Created with Sketch. 119.32KB
CUV SCENESSE breakthrough featured in peer-reviewed editorial
20/03/15 download Created with Sketch. 115.97KB
CUV Clinuvel Newsletter - March 2015
12/03/15 download Created with Sketch. 1.09MB
MPL +S&P DJ Indices Announces March Quarterly Review
06/03/15PRICE SENSITIVE download Created with Sketch. 100.19KB
CUV Appendix 3B
02/03/15 download Created with Sketch. 550KB
CUV Half Yearly Report and Accounts
25/02/15PRICE SENSITIVE download Created with Sketch. 265.55KB
CUV Appendix 4C - quarterly
30/01/15PRICE SENSITIVE download Created with Sketch. 138.2KB
CUV Change of Director's Interest Notice
23/01/15 download Created with Sketch. 728.77KB
CUV Appendix 3B
23/01/15 download Created with Sketch. 549.52KB
CUV Initial Director's Interest Notice
21/01/15 download Created with Sketch. 342.33KB
CUV Clinuvel appoints new Non-Executive Director
21/01/15 download Created with Sketch. 210.85KB
CUV European Commission approves SCENESSE
23/12/14PRICE SENSITIVE download Created with Sketch. 275.65KB
CUV Change of Director's Interest Notice x 3
23/12/14 download Created with Sketch. 681.88KB
CUV Appendix 3B
23/12/14 download Created with Sketch. 544.6KB
CUV Long term use of SCENESSE in EPP published in BJD
15/12/14 download Created with Sketch. 121.02KB
CUV Change in substantial holding
05/12/14 download Created with Sketch. 278.54KB
CUV Change of Director's Interest Notice * 4
04/12/14 download Created with Sketch. 857.15KB
CUV Appendix 3B
04/12/14 download Created with Sketch. 548.6KB
CUV Investor Update Presentation
04/12/14 download Created with Sketch. 1.13MB
CUV Results of Meeting
28/11/14 download Created with Sketch. 101.25KB
CUV Chairman's Address
28/11/14 download Created with Sketch. 87.82KB
CUV CEO's AGM presentation
28/11/14 download Created with Sketch. 4.08MB
CUV Letter to Shareholders
05/11/14 download Created with Sketch. 256.29KB
CUV Letter to Shareholders
03/11/14 download Created with Sketch. 299.92KB
CUV Appendix 4C - quarterly
29/10/14PRICE SENSITIVE download Created with Sketch. 150.11KB
CUV Clinuvel to host investor teleconference
28/10/14 download Created with Sketch. 83.46KB
CUV Annual Report to shareholders
27/10/14 download Created with Sketch. 1.18MB
CUV Notice of Annual General Meeting/Proxy Form
27/10/14 download Created with Sketch. 665.02KB
CUV SCENESSE attains breakthrough European Market Authorisation
27/10/14PRICE SENSITIVE download Created with Sketch. 131.83KB
CUV Trading Halt
24/10/14PRICE SENSITIVE download Created with Sketch. 240.88KB
CUV AGM Date
10/10/14 download Created with Sketch. 216.29KB
CUV Lapse and Forfeit of Unlisted Conditional Performance Rights
10/10/14 download Created with Sketch. 187.82KB
CUV SCENESSE data to be presented at EADV conference
08/10/14 download Created with Sketch. 92.14KB
CUV EMA Oral Explanation Update
26/09/14PRICE SENSITIVE download Created with Sketch. 90.07KB
CUV Clinuvel invited to present at EMA's CHMP plenary session
22/09/14 download Created with Sketch. 299.84KB
CUV Clinuvel enters a joint venture with Biotech Lab Singapore
19/09/14PRICE SENSITIVE download Created with Sketch. 281.14KB
CUV JAMA Dermatology publishes SCENESSE vitiligo study results
19/09/14PRICE SENSITIVE download Created with Sketch. 152KB
CUV Response to ASX Price Query
16/09/14PRICE SENSITIVE download Created with Sketch. 536.23KB
CUV Change in substantial holding
12/09/14 download Created with Sketch. 890.53KB
CUV Change in substantial holding
11/09/14 download Created with Sketch. 1.12MB
CUV Preliminary Final Report
25/08/14PRICE SENSITIVE download Created with Sketch. 2.05MB
CUV Chairman's Update
18/08/14 download Created with Sketch. 292.16KB
CUV Clinuvel declines unsolicited proposal from Retrophin
08/08/14PRICE SENSITIVE download Created with Sketch. 118.72KB
CUV Appendix 3B
07/08/14 download Created with Sketch. 549.84KB
CUV Appendix 4C - quarterly
31/07/14PRICE SENSITIVE download Created with Sketch. 33.46KB
CUV Final Director's Interest Notice
31/07/14 download Created with Sketch. 109.47KB
CUV Becoming a substantial holder
30/07/14 download Created with Sketch. 265.21KB
CUV Becoming a substantial holder
30/07/14 download Created with Sketch. 257.08KB
CUV Proposal to acquire all the outstanding shares in Clinuvel P
28/07/14 download Created with Sketch. 999.46KB
CUV Mr Jack Wood
28/07/14 download Created with Sketch. 85.15KB
CUV Clinuvel receives an unsolicited bid for the Company
28/07/14PRICE SENSITIVE download Created with Sketch. 89.73KB
CUV Clinuvel Newsletter July 2014
16/07/14 download Created with Sketch. 328.13KB
CUVUS orphan-drug designation in Hailey-Hailey Disease
22/05/14PRICE SENSITIVE download Created with Sketch. 313.99KB
CUVs.708A Notice
20/05/14 download Created with Sketch. 34.01KB
CUVBecoming a substantial holder
20/05/14 download Created with Sketch. 52.63KB
CUVAppendix 3B
20/05/14 download Created with Sketch. 512.46KB
CUVEuro orphan designation in Hailey-Hailey Disease - SCENESSE
19/05/14 download Created with Sketch. 118.76KB
CUVManagement Update
19/05/14PRICE SENSITIVE download Created with Sketch. 415.41KB
CUVClinuvel placement
14/05/14PRICE SENSITIVE download Created with Sketch. 427.27KB
CUVTrading Halt Request
12/05/14 download Created with Sketch. 155.48KB
CUVTrading Halt
12/05/14PRICE SENSITIVE download Created with Sketch. 77.85KB
CUVPhase II vitiligo study commences in Singapore
06/05/14PRICE SENSITIVE download Created with Sketch. 368.83KB
CUVAppendix 4C - quarterly
17/04/14PRICE SENSITIVE download Created with Sketch. 150.32KB
CUVLapse and Forfeit of Unlisted Conditional Performance Rights
14/04/14 download Created with Sketch. 189.38KB
CUVClinuvel Newsletter April 2014
14/04/14 download Created with Sketch. 1.72MB
CUVSCENESSE data to feature at American Academy of Dermatology
20/03/14 download Created with Sketch. 129.81KB
CUVHalf Yearly Report and Accounts
26/02/14PRICE SENSITIVE download Created with Sketch. 320.92KB
CUVPhase II study starts in skin disorder Hailey-Hailey Disease
10/02/14PRICE SENSITIVE download Created with Sketch. 301.25KB
CUVClinuvel Newsletter
04/02/14 download Created with Sketch. 391.27KB
(20min delay)
Last
$15.69
Change
0.070(0.45%)
Mkt cap ! $786.1M
Open High Low Value Volume
$15.68 $15.98 $15.58 $1.543M 98.04K

Buyers (Bids)

No. Vol. Price($)
1 256 $15.61
 

Sellers (Offers)

Price($) Vol. No.
$15.77 256 1
View Market Depth
Last trade - 16.10pm 28/05/2024 (20 minute delay) ?
Last
$15.70
  Change
0.070 ( 0.36 %)
Open High Low Volume
$15.68 $15.97 $15.60 6072
Last updated 15.59pm 28/05/2024 ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.